Latest News and Press Releases

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...

Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, June 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part 2 Expected in Third Quarter of 2023 Second...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...